Organization (Industry)
Dong-A Pharmaceutical (South Korea)
ClinicalTrials.gov lists Dong-A Pharmaceutical (South Korea) as lead sponsor of 22 trials. It has 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Dong-A Pharmaceutical (South Korea): 22 lead-sponsored trials and 1 legal-entity registration.
Disease areas (34)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Sexual Dysfunction, Physiological | 4 |
| Diabetes Mellitus | 3 |
| Erectile Dysfunction | 3 |
| Cholangiocarcinoma | 2 |
| Dementia | 2 |
Showing 5 of 34 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2021 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2014 | 2 |
| 2013 | 6 |
| 2012 | 10 |
| 2011 | 6 |
| 2010 | 6 |
| 2009 | 3 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: none of the 22 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DA-5515 | 1 |
| Naftopidil | 1 |
| Motilitone | 1 |
| Evogliptin | 2 |
| METFORMIN | 1 |
Showing 5 of 6 approved assets.
Journals published in (40)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Stroke | 10 |
| The New England journal of medicine | 5 |
| Clinical therapeutics | 4 |
| Circulation | 2 |
| European heart journal | 2 |
Showing 5 of 40 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 23 | 0 | 2019-05-07 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 8 | 2019-09-20 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| DONG-A PHARMACEUTICAL CO., LTD. | Seoul, KR | FDA |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Hyuk moon Kim | Co sponsors trial with | 1 |
| National Cancer Center, Korea | Co sponsors trial with | 1 |
Latest dated events (71)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2024-01-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2021-04-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2019-09-20 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2019-05-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2018-01-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 71 events.
Biomarker capability evidence (77)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| PRL | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial collaborator | Named in trial exclusion criteria |
| ATP12A | Trial collaborator | Named in trial exclusion criteria |
| ATP4A | Trial collaborator | Named in trial exclusion criteria |
| ATP4A | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 77 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.